CD8A and neoplasm: JAK mutations lower the ability of CD8+ T cells to recognise tumour cells and are implicated in primary resistance to PD-1 inhibitors.67 Therapy resistance can be correlated with increased expression of VEGF,68 which affects CD8+ T-cell functionality both directly and indirectly via the suppression of dendritic cell maturation and recruitment of suppressive cell populations.69